Arbutus Biopharma Corp
ABUS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001447028
No open-market purchases or sales by Arbutus Biopharma Corp insiders were filed in the last 90 days; 176 institutions reported holding it in 13F filings for Q2 2026, worth $674.9M in total; no superinvestor holds it.
Q1 2023 vs. Q4 2022
How the institutions holding Arbutus Biopharma Corp changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Of which not filed for Q1 2023 | Q1 2023 | Change |
|---|---|---|---|---|
| Holders | 114 | 1 | 122 | +9 |
| Shares | 54.2M | 200.0K | 62.5M | +8.48M (+15.7%) |
| Value | $126.3M | $466.0K | $189.3M | +$63.4M (+50.4%) |
1 institution that held it in Q4 2022 haven't filed for Q1 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (20)
Institutions that held Arbutus Biopharma Corp at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Woodline Partners LP | 2,657,605 | $8.05M | 0.11% |
| Kennedy Capital Management, Inc. | 392,843 | $1.19M | 0.04% |
| Two Sigma Investments, LP | 369,777 | $1.12M | 0.00% |
| Cubist Systematic Strategies, LLC | 119,193 | $361.2K | 0.00% |
| Jump Financial, LLC | 68,974 | $209.0K | 0.01% |
| CM Wealth Advisors LLC | 37,096 | $94.0K | 0.02% |
| Scotia Capital Inc. | 29,190 | $88.5K | 0.00% |
| Verition Fund Management LLC | 25,371 | $76.9K | 0.00% |
| Qube Research & Technologies Ltd | 22,024 | $66.7K | 0.00% |
| Two Sigma Securities, LLC | 21,235 | $64.3K | 0.01% |
| Dark Forest Capital Management LP | 17,155 | $52.0K | 0.01% |
| Ergoteles LLC | 15,000 | $45.5K | 0.00% |
| Arete Wealth Advisors, LLC | 15,000 | $45.0K | 0.00% |
| First Manhattan Co | 14,000 | $42.4K | 0.00% |
| Victory Capital Management Inc | 13,297 | $40.3K | 0.00% |
| Sawtooth Solutions, LLC | 10,813 | $32.8K | 0.00% |
| Bleakley Financial Group, LLC | 10,813 | $32.8K | 0.00% |
| Brown, Lisle/Cummings, Inc. | 7,500 | $22.7K | 0.01% |
| Russell Investments Group, Ltd. | 1,344 | $4.07K | 0.00% |
| GPS Wealth Strategies Group, LLC | 700 | $2.12K | 0.00% |
Sold out (11)
Institutions that held Arbutus Biopharma Corp at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Oasis Management Co Ltd. | 1,088,895 | $2.54M |
| Jacob Asset Management of New York LLC | 187,400 | $436.6K |
| Caption Management, LLC | 50,000 | $116.5K |
| Man Group plc | 44,900 | $104.6K |
| Balyasny Asset Management LLC | 14,633 | $34.1K |
| Dynamic Technology Lab Private Ltd | 13,630 | $32.0K |
| Squarepoint Ops LLC | 13,650 | $31.8K |
| Alpine Global Management, LLC | 10,198 | $24.0K |
| Zurcher Kantonalbank (Zurich Cantonalbank) | 6,178 | $14.4K |
| Credit Suisse AG | 1,102 | $2.57K |
| Allspring Global Investments Holdings, LLC | 1,000 | $2.33K |
Not filed for Q1 2023 yet (1)
Institutions that held Arbutus Biopharma Corp at the end of Q4 2022 and haven't filed a 13F for Q1 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Kepos Capital LP | 200,000 | $466.0K |